Starling Oncology, Inc. Business Acquisition, Pro Forma Revenue
Starling Oncology, Inc. (DFPH) reported Business Acquisition, Pro Forma Revenue of $326.35 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-28.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2024-03-28
- Starling Oncology, Inc. business acquisition, pro forma revenue for the quarter ending 2022-12-31 was $62.59M, a 3.23% increase year-over-year.
- Starling Oncology, Inc. business acquisition, pro forma revenue for the quarter ending 2022-09-30 was $66.19M, a 10.60% increase year-over-year.
- Starling Oncology, Inc. business acquisition, pro forma revenue for the quarter ending 2022-06-30 was $62.39M, a 14.56% increase year-over-year.
- Starling Oncology, Inc. business acquisition, pro forma revenue for the quarter ending 2021-12-31 was $60.63M.
- Starling Oncology, Inc. business acquisition, pro forma revenue for fiscal 2023 was $326.35M, a 27.10% increase from fiscal 2022.
- Starling Oncology, Inc. business acquisition, pro forma revenue for fiscal 2022 was $256.76M, a 9.70% increase from fiscal 2021.
- Starling Oncology, Inc. business acquisition, pro forma revenue for fiscal 2021 was $234.05M, a 15.69% increase from fiscal 2020.
- Starling Oncology, Inc. business acquisition, pro forma revenue for fiscal 2020 was $202.32M.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 12 month | Business Acquisition, Pro Forma Revenue 12 month as first filed |
|---|---|---|---|---|---|
| 2023-12-31 | $326.35M 10-K · filed 2024-03-28 | ||||
| 2022-12-31 | $62.59M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $128.78M derived: sum of 2 quarters · filed 2024-03-28 | $191.17M derived: sum of 3 quarters · filed 2024-03-28 | $256.76M 10-K · filed 2024-03-28 | $266.23M 10-K · filed 2023-03-16 |
| 2022-09-30 | $66.19M 10-Q · filed 2022-11-09 | $128.58M derived: sum of 2 quarters · filed 2022-11-09 | $194.17M 10-Q · filed 2022-11-09 | ||
| 2022-06-30 | $62.39M 10-Q · filed 2022-08-09 | $122.10M 10-Q · filed 2022-08-09 | |||
| 2021-12-31 | $60.63M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $120.48M derived: sum of 2 quarters · filed 2023-03-16 | $174.93M derived: sum of 3 quarters · filed 2023-03-16 | $234.05M 10-K · filed 2023-03-16 | $3.02M 10-K · filed 2022-03-11 |
| 2021-09-30 | $59.85M 10-Q · filed 2022-11-09 | $114.31M derived: sum of 2 quarters · filed 2022-11-09 | $173.42M 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $54.45M 10-Q · filed 2022-08-09 | $107.65M 10-Q · filed 2022-08-09 | |||
| 2020-12-31 | $202.32M 10-K · filed 2022-03-11 |